Sanofi-Aventis is born
Executive Summary
Sanofi-Synthelabo and Aventis merger closes Aug. 20, creating third largest pharma company, Sanofi-Aventis, with Sanofi obtaining control of 95.5% of Aventis' share capital. Completion of the merger follows required divestiture of Estorra (1"The Pink Sheet" Aug. 16, 2004, p. 34)...
You may also be interested in...
Sanofi-Aventis U.S. headquarters
U.S. headquarters for Sanofi-Aventis will be located in Bridgewater, N.J., the firm announced Oct. 13. Bridgewater serves as the U.S. headquarters for Aventis, while Sanofi-Synthelabo is located in New York. Most of the 600 Sanofi employees will be offered a position in Bridgewater, Sanofi-Aventis said. The consolidation of U.S. operations is expected to take several months. Aventis and Sanofi completed their merger Aug. 20 (1"The Pink Sheet" Aug. 30, 2004, In Brief)...
Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested
Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”